Pfizer Ventures could be in line for an exit after AbbVie purchased a buyout option for Parkinson's disease drug developer Mitokinin.
Mitokinin, a US-based neurodegenerative disease drug developer backed by Pfizer, sold an exclusive buyout option to another pharmaceutical firm, AbbVie, on Tuesday.
AbbVie made an upfront payment of undisclosed size for the right to acquire Mitokinin once it has completed investigational new drug-enabling studies for its lead asset, a potential therapy for Parkinson’s disease for which the companies have negotiated a collaborative research plan.
Mitokinin’s approach relies on increasing the activity of Pink1, a gene linked to Parkinson’s disease, in…
